David B. Matchar, MD

Articles by David B. Matchar, MD

Does Distance Modify the Effect of Self-Testing in Oral Anticoagulation?

ByAdam J. Rose, MD, MSc,Ciaran S. Phibbs, PhD,Lauren Uyeda, MA,Pon Su, MS,Robert Edson, MA,Mei-Chiung Shih, PhD,Alan Jacobson, MD,David B. Matchar, MD

January 20th 2016

Self-testing of anticoagulation improves outcomes, but is expensive. One might assume it is more helpful for patients living farther from care, but the authors disprove this assumption.

Medicare HMO Penetration and Mortality Outcomes of Ischemic Stroke

ByJohn Bian, PhD,William H. Dow, PhD,David B. Matchar, MD

January 1st 2006

Pharmacoeconomics of Atrial Fibrillation and Stroke Prevention

ByCheryl D. Bushnell, MD, MHS,David B. Matchar, MD

April 1st 2004

A Clinical Decision and Economic Analysis Model of Cancer Pain Management

ByAmy P. Abernethy, MD,Gregory P. Samsa, PhD,David B. Matchar, MD

October 1st 2003

Disease Management in Healthcare Organizations: Results of In-Depth Interviews with Disease Management Decision Makers

ByDavid J. Whellan, MD,Elizabeth J. Cohen, MBA,David B. Matchar, MD,Robert M. Califf, MD

July 1st 2002

Latest Updated Articles

Does Distance Modify the Effect of Self-Testing in Oral Anticoagulation?
January 20th 2016
Disease Management in Healthcare Organizations: Results of In-Depth Interviews with Disease Management Decision Makers
July 1st 2002
Medicare HMO Penetration and Mortality Outcomes of Ischemic Stroke
January 1st 2006
Pharmacoeconomics of Atrial Fibrillation and Stroke Prevention
April 1st 2004
A Clinical Decision and Economic Analysis Model of Cancer Pain Management
October 1st 2003

David B. Matchar, MD

Articles by David B. Matchar, MD

Does Distance Modify the Effect of Self-Testing in Oral Anticoagulation?

Medicare HMO Penetration and Mortality Outcomes of Ischemic Stroke

Pharmacoeconomics of Atrial Fibrillation and Stroke Prevention

A Clinical Decision and Economic Analysis Model of Cancer Pain Management

Disease Management in Healthcare Organizations: Results of In-Depth Interviews with Disease Management Decision Makers

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Monoclonal Antibodies Had Varying Efficacy in Treating MG